KPV

Lys-Pro-Val α-MSH C-terminal tripeptide

≥ 99.0% · target, verify batch COACAS 67727-97-3RUO

Research statusPreclinical; no FDA-approved indication and no identified administered-human study reference context · supplied material is RUO

Supplied formTripeptide (linear)

Lead time7–14 days

KPV — Lyophilized material; confirm released-lot appearance on the COA

Representative packaging image · verify the ordered lot

Decision summary

Key benefits

Research value includes PepT1-mediated peptide uptake, NF-kB/MAPK and cytokine assays, mouse inflammatory models, delivery-system engineering, ex vivo skin transport and comparison of alpha-MSH-derived fragments
No human anti-inflammatory, gastrointestinal, skin, immune, joint, antimicrobial or wound-healing benefit has been established.

Published research context is presented for literature orientation only. It is not a dosing, treatment or human-use instruction.

Qualification data

Specifications to confirm against the released lot

CAS: 67727-97-3
Formula: C₁₆H₃₀N₄O₄
Molecular weight: Approximately 342.44 g/mol
Appearance: Lyophilized material; confirm released-lot appearance on the COA
Purity: ≥ 99.0% · target, verify batch COA
Storage: Follow the released lot's COA and stability data. Specify free acid or salt, temperature, light, moisture, matrix, concentration, container, adsorption, freeze-thaw limits and validated hold time. Do not use generic refrigerated-solution guidance across formulations.
MOQ: On request
Lead time: 7–14 days

PubChem CID 125672

Qualification matrix

Identity, purity and content are separate release questions.

Identity

Confirm the stated molecule and supplied form. Start with the matching batch COA; request sequence-level evidence only when the buyer's written procedure requires it and availability or a separate scope has been agreed.

Purity

Review RP-HPLC method conditions, wavelength, integration and related-peak handling. A percentage without the method is not enough.

Content

Net peptide content is not the same as gross lyophilized powder weight. Ask which assay supports the stated amount and whether water/counter-ion is addressed.

Stability

Define long-term storage and transit exposure separately. Cold-chain can be quoted when the buyer’s risk assessment requires it and adds cost.

Research context

What researchers study about KPV

KPV is the free-acid tripeptide H-Lys-Pro-Val-OH, corresponding to residues 11-13 at the C-terminus of alpha-MSH. Cell and animal studies report anti-inflammatory signaling and activity in models including mouse colitis. Many later results depend on nanoparticles, hydrogels, prodrugs, microneedles or iontophoresis. FDA states that it has not identified human exposure data for KPV drug products by any route and lacks information needed to determine whether KPV would harm humans.

Appropriate research contexts include peptide-transporter biology, experimental inflammatory signaling, mouse colitis or injury models, alpha-MSH-fragment comparisons, delivery-system development and analytical method validation
These are research purposes, not approved human indications.

Mechanism context

The question the literature is testing

Experimental studies associate KPV with PepT1 uptake and modulation of NF-kB, MAPK and inflammatory cytokines. Reports differ on melanocortin-receptor dependence, and effects may vary by cell type, model and formulation. KPV should not be described as guaranteed non-melanogenic, non-immunosuppressive or active for 12-24 hours in humans without direct evidence.

Evidence map

Research routes and exposure context

Evidence tierApproved finished-product context

Research areaImmune signaling research

Routes reported in sources

SubcutaneousOralTopical

Dose / exposure contextProtocol-specific; verify the cited primary source

Routes and exposure contexts summarize cited studies or approved finished-product labels. They are not instructions for administering this RUO material; no customer dose is provided.

Evidence boundaries

Compatibility, limitations and decision context

Research-use-only material; not for human or veterinary administration
FDA has not identified human exposure data for KPV drug products by any route and lacks important safety information
Animal and cell results cannot establish systemic, immunologic, reproductive, genotoxic or long-term human safety.

Interactions reported in the literature

No formal human interaction or peptide-stacking data exist
Do not infer synergy or compatibility with BPC-157, TB-500, LL-37, GHK-Cu, thymosin alpha-1 or melanotan II from community protocols
Experimental combinations require single-component, vehicle and formulation controls.

Literature context is not a supplier release result or human-use instruction. Follow your institution's approved laboratory risk assessment.

Factory batch documentation

KPV factory batch COAs

KPV 5 mg Factory batch COA protected preview

KPV5 mg · WHJLP-KP5-260601-A

KPV 10 mg Factory batch COA protected preview

KPV10 mg · WHJLP-KP10-260601-A

Representative records, refreshed periodically

Published COAs show representative factory batches and may not be the latest available. For a current quote or shipment, our sales team can confirm the applicable lot and provide its COA.

Independent testing, arranged on request

Third-party reports are not routinely published. If independent verification is required, we can agree the laboratory, method, acceptance criteria and remedy before testing. If the agreed specification is not met, an appropriate resolution—including a refund where applicable—can be discussed under the agreed terms. Unless otherwise agreed in writing, the buyer pays the cost of this optional testing.

Help reviewing your COA

Need help reading a factory COA or third-party report? Our sales team can clarify test items, specifications and how the results relate to the lot under discussion.

Ask for the current packet, not a generic certificate

Require complete sequence and termini, intact mass, peptide content, chromatographic related-peptide profile, counterion, water and residual solvents
Add matrix-specific stability, bioburden, endotoxin or sterility controls only as required by the actual research model
HPLC area purity above 98%, appearance, clarity, target pH or a generic third-party COA alone is insufficient.

Released-batch COARP-HPLC result and method contextIdentity result appropriate to the moleculeWater / counter-ion context where relevantSDS and handling statementAdditional testing scoped on request

Available fills

Quote the fill and pack configuration you need

Reference SKUFillBase pack

KPV-05MG5 mg10 vials

KPV-10MG10 mg10 vials

Handling

Storage in the lab and temperature during transit are different decisions

Follow the released lot's COA and stability data. Specify free acid or salt, temperature, light, moisture, matrix, concentration, container, adsorption, freeze-thaw limits and validated hold time. Do not use generic refrigerated-solution guidance across formulations.

State destination, season, acceptable transit exposure and whether your protocol requires insulated or cold-chain service. Additional temperature-control cost is quoted explicitly.

Buyer FAQ

Terms to settle before the purchase order

Can a buyer arrange third-party testing?+

Yes. Testing must be performed by a mutually accepted, established specialist laboratory. Fee allocation, specification, sampling, method and acceptance rule must be agreed before testing; if an agreed independent result shows nonconformance, the remedy follows the signed order terms. Unless otherwise agreed in writing, the buyer pays the cost of this optional testing.

Does HPLC purity prove peptide content?+

No. Chromatographic purity describes the relative peak profile under a stated method. Identity, water, counter-ion, residual solvents and assay/content may require separate methods.

Is cold-chain shipping always required?+

Not always. Heat can accelerate degradation, especially during summer and long transit. Cold-chain reduces exposure but raises cost. State the destination and stability risk so the right service can be quoted.

How are payment terms handled?+

Available methods and milestones depend on order value, destination and project type. The pro forma invoice should state currency, bank details, fees, payment milestones and the release condition.

Why must the testing laboratory understand peptide chemistry?+

Free-base and salt forms, hydrophilic and hydrophobic sequences, aggregation and adsorption can change sample preparation and method suitability. Use a laboratory experienced with the molecule class.

External qualification references

WHO good storage and distribution practices IATA Temperature Control Regulations ISO/IEC 17025 laboratory competence 21 CFR 211.84 component testing and supplier COA controls

These are buyer-qualification references, not claims that this RUO material is regulated, certified or released under those frameworks. Applicability depends on the buyer's workflow and jurisdiction.

Selected sources

Literature behind the research context

Core evidence: Dalmasso et al. 2008 (PMID 18061177), PepT1 uptake and cell/mouse colitis work; melanocortin-fragment reviews (PMID 17934097 and related literature); Xiao et al. 2017 (PMID 28143741), formulated nanoparticle/hydrogel delivery; Cheng et al. 2026 (PMID 41533788), a KPV prodrug platform; Pawar et al. 2017 (PMID 28343991), ex vivo human-skin delivery; and Schaible et al. 2013 (PMID 23940690), mouse TBI. FDA's compounding-risk page controls the human-data warning.

01
PepT1-mediated tripeptide KPV uptake reduces intestinal inflammation
Gastroenterology · 2008 · peer-reviewed original research
Open source
02
alpha-MSH related peptides: a new class of anti-inflammatory and immunomodulating drugs
Annals of the Rheumatic Diseases · 2007 · review article
Open source
03
α-Melanocyte-Stimulating Hormone and Related Tripeptides: Biochemistry, Antiinflammatory and Protective Effects in Vitro and in Vivo, and Future Perspectives for the Treatment of Immune-Mediated Inflammatory Diseases
Endocrine Reviews · 2008 · peer-reviewed review article
Open source
04
Orally Targeted Delivery of Tripeptide KPV via Hyaluronic Acid-Functionalized Nanoparticles Efficiently Alleviates Ulcerative Colitis
Molecular Therapy · 2017 · peer-reviewed original research
Open source
05
Inflammation-triggered self-immolative conjugates enable oral peptide delivery by overcoming gastrointestinal barriers
Science Advances · 2026 · peer-reviewed original research
Open source
06
Transdermal Iontophoretic Delivery of Lysine-Proline-Valine (KPV) Peptide Across Microporated Human Skin
Journal of Pharmaceutical Sciences · 2017 · peer-reviewed original research
Open source
07
Single Administration of Tripeptide α-MSH(11-13) Attenuates Brain Damage by Reduced Inflammation and Apoptosis after Experimental Traumatic Brain Injury in Mice
PLoS One · 2013 · peer-reviewed original research
Open source
08
New insights into the functions of alpha-MSH and related peptides in the immune system
Annals of the New York Academy of Sciences · 2003 · peer-reviewed review article
Open source

Product FAQ

Questions buyers ask about KPV

Why is KPV studied as an α-MSH-derived tripeptide, and what should not be inferred?+

KPV is the free-acid Lys-Pro-Val sequence corresponding to residues 11–13 of α-MSH. Cell and animal studies associate this fragment with inflammatory-signaling changes, sometimes through melanocortin-independent mechanisms. That makes it a useful reductionist research tool, but it does not prove that KPV retains a fixed fraction of every α-MSH effect, is universally non-melanogenic or non-immunosuppressive, or has an administered-human anti-inflammatory benefit.

Does KPV have established oral bioavailability?+

No qualified human absolute-bioavailability or pharmacokinetic study was identified. PepT1 uptake and mouse-colitis experiments support transporter and local-gut research, but many later studies use nanoparticles, hydrogels, prodrugs or other delivery systems. Activity after an oral or luminal animal protocol does not establish protease resistance, systemic absorption or an effective oral formulation in people. Specify the exact analyte and delivery system when interpreting or reproducing a study.

What contamination controls are appropriate for inflammation-focused KPV research?+

Endotoxin or microbial contamination can confound cytokine, NF-κB, macrophage and other inflammatory readouts. Set limits from the actual model, route, concentration and institutional protocol, and use a validated method with suitable interference controls; LAL is not automatically appropriate for every matrix. Bioburden, endotoxin or sterility are different attributes and should be ordered only as required. Confirm test methods, limits, sample requirements and lead time in the quotation rather than assuming they are standard release tests.

KPV

Key benefits

Specifications to confirm against the released lot

Identity, purity and content are separate release questions.

What researchers study about KPV

The question the literature is testing

Research routes and exposure context

Compatibility, limitations and decision context

Interactions reported in the literature

KPV factory batch COAs

Ask for the current packet, not a generic certificate

Quote the fill and pack configuration you need

Storage in the lab and temperature during transit are different decisions

Terms to settle before the purchase order

Literature behind the research context

PepT1-mediated tripeptide KPV uptake reduces intestinal inflammation

alpha-MSH related peptides: a new class of anti-inflammatory and immunomodulating drugs

α-Melanocyte-Stimulating Hormone and Related Tripeptides: Biochemistry, Antiinflammatory and Protective Effects in Vitro and in Vivo, and Future Perspectives for the Treatment of Immune-Mediated Inflammatory Diseases

Orally Targeted Delivery of Tripeptide KPV via Hyaluronic Acid-Functionalized Nanoparticles Efficiently Alleviates Ulcerative Colitis

Inflammation-triggered self-immolative conjugates enable oral peptide delivery by overcoming gastrointestinal barriers

Transdermal Iontophoretic Delivery of Lysine-Proline-Valine (KPV) Peptide Across Microporated Human Skin

Single Administration of Tripeptide α-MSH(11-13) Attenuates Brain Damage by Reduced Inflammation and Apoptosis after Experimental Traumatic Brain Injury in Mice

New insights into the functions of alpha-MSH and related peptides in the immune system

Questions buyers ask about KPV

Compare adjacent molecules and documentation needs.

LL-37

BPC-157

Thymalin

Thymosin Alpha 1